Neonatal Hemolytic Anemia: Exchange Transfusion Indications

Neonatal haemolytic anaemia occurs when red blood cells are destroyed faster than a newborn can replace them. The resulting unconjugated bilirubin may rise quickly, while falling haemoglobin can impair oxygen delivery. In severe cases, exchange transfusion remains a time-critical treatment that can reduce bilirubin, remove circulating antibodies and replace damaged erythrocytes.

The most familiar cause is immune-mediated haemolysis from maternal antibodies, particularly anti-D, anti-c, anti-E or ABO incompatibility. Other causes include glucose-6-phosphate dehydrogenase deficiency, hereditary spherocytosis, pyruvate kinase deficiency, infection and less common red-cell membrane or enzyme disorders. A baby may look well initially, so laboratory monitoring and awareness of risk factors are essential.

For Australian clinicians, decisions should be made with the neonatal intensive care unit, transfusion service and paediatric haematology team. A newborn in a regional maternity unit may require urgent retrieval to Sydney, Melbourne, Brisbane, Perth, Adelaide, Canberra or another tertiary centre. Treatment should begin while transport is arranged when bilirubin is approaching a dangerous level.

The FAOPS 2020 archive provides historical context for the region’s perinatal and neonatal medicine community. Its original congress was cancelled during the COVID-19 pandemic, but the clinical priority remains current: recognise rapidly progressive haemolysis, start effective phototherapy promptly and escalate before bilirubin reaches a neurotoxic concentration.

When Haemolysis Becomes an Emergency

Exchange transfusion is considered when total serum bilirubin reaches the exchange threshold on an appropriate age-specific treatment chart, particularly when intensive phototherapy and intravenous support have failed to slow the rise. The threshold depends on gestational age, postnatal age in hours, albumin concentration, clinical stability and neurotoxicity risk factors.

A baby with isoimmune haemolysis, sepsis, significant prematurity, acidosis or low albumin has less tolerance for bilirubin toxicity. The rate of bilirubin increase also matters. A steep rise, such as approximately 8.5 micromol/L per hour or more in a high-risk setting, should prompt urgent senior review, although local protocols may use different triggers.

Urgent exchange is also indicated when there are clinical signs of acute bilirubin encephalopathy. Early features may include poor feeding, lethargy, hypotonia and an abnormal cry. Progression can involve irritability, hypertonia, retrocollis, opisthotonus, apnoea or seizures. Neurological signs require immediate treatment and should not be deferred while waiting for a repeat bilirubin result.

Confirming Cause And Severity

Initial testing generally includes total and direct bilirubin, full blood count, reticulocyte count, blood film, maternal and infant blood groups, direct antiglobulin test and, when relevant, glucose-6-phosphate dehydrogenase testing. Haemoglobin provides a baseline, but a single value does not show how quickly anaemia is developing. Reticulocytosis, nucleated red cells and spherocytes can support haemolysis, though findings vary with the cause.

A maternal history of anti-D or another clinically significant antibody is highly relevant. Antibody screening during pregnancy and appropriate RhD immunoglobulin use have reduced severe Rh disease in Australia, but sensitisation still occurs. ABO haemolysis can appear in a first pregnancy and may be missed if attention is focused only on RhD incompatibility.

Cord blood results should be interpreted alongside the baby’s examination and bilirubin trajectory. Pallor, jaundice within the first 24 hours, hepatosplenomegaly, tachycardia, respiratory distress or hydrops suggest substantial disease. Severe anaemia with modest bilirubin may require a carefully planned red-cell transfusion rather than exchange; the two treatments address different physiological problems.

Reading Bilirubin Thresholds

Treatment charts are designed to prevent dangerous variation in practice. They plot total serum bilirubin against the baby’s age in hours and usually provide separate lines for gestational age and neurotoxicity risk. Transcutaneous bilirubin can support screening, but a serum measurement is required when treatment or exchange is being considered.

The exchange line is not a target to wait for. If bilirubin is within a narrow margin of that line, preparation should begin immediately because obtaining compatible blood, placing umbilical access and assembling an experienced team take time. Intensive phototherapy should continue during preparation, with the light source positioned correctly and as much skin exposed as safely possible.

Intravenous immunoglobulin may be considered for selected cases of immune-mediated haemolysis when bilirubin continues to rise despite intensive phototherapy. Evidence and local recommendations vary, and immunoglobulin does not replace exchange transfusion when the exchange threshold is reached or neurological signs are present.

Preparing For Exchange Transfusion

The procedure should occur in a neonatal intensive care environment or a specialist setting with trained staff, continuous cardiorespiratory monitoring and immediate access to resuscitation equipment. Two reliable vascular routes are needed where possible. An umbilical venous catheter is commonly used for withdrawal and infusion, while an arterial line may be used for monitoring or sampling according to local policy.

The transfusion laboratory needs advance notice. Blood is selected according to maternal and infant antibodies, compatibility testing and the urgency of treatment. In Australia, hospitals coordinate with Australian Red Cross Lifeblood and their local blood bank, and emergency-release arrangements differ by service. Waiting for a perfect non-urgent match is unsafe when bilirubin neurotoxicity is imminent, but blood selection must still be directed by transfusion specialists.

Parents or guardians should receive a clear explanation of the indication, expected benefit, alternatives, possible complications and the urgency of consent. Documentation should include bilirubin values, haemoglobin, antibody results, treatment already given and the clinical response. If transfer from a rural or outer-suburban hospital is required, the retrieval team should be involved early rather than after deterioration.

The Procedure And Its Risks

A double-volume exchange replaces approximately two circulating blood volumes, often around 160–180 mL/kg in a term newborn, although the prescribed volume depends on gestation, weight, haemoglobin and local protocol. Small aliquots of blood are removed and replaced sequentially. This reduces circulating bilirubin and maternal antibody while supplying compatible red cells.

The procedure requires meticulous recording of every withdrawal and infusion. Blood may be warmed according to protocol, and the infant’s temperature, glucose, calcium, blood gases, electrolytes, blood pressure, heart rhythm and oxygenation need repeated assessment. Feeding is usually withheld during the procedure, with glucose-containing intravenous fluid used as prescribed.

Potential complications include hypocalcaemia from citrate, hypoglycaemia or hyperglycaemia, hyperkalaemia, thrombocytopenia, coagulopathy, arrhythmia, catheter-related bleeding, thrombosis, infection, transfusion reactions and necrotising enterocolitis. Sudden shifts in blood volume can also cause hypotension or cardiac strain. These risks explain why exchange transfusion is reserved for severe disease and performed by an experienced multidisciplinary team.

Care After The Exchange

Bilirubin may rebound after the exchange because bilirubin continues to be produced and antibodies can remain in tissues or plasma. Intensive phototherapy should generally continue, and total bilirubin should be checked at intervals specified by the neonatal service. A second exchange is uncommon but may be required when levels remain dangerous or rise rapidly again.

Haemoglobin and reticulocyte counts need follow-up because ongoing haemolysis can continue for days or weeks. Babies with maternal red-cell antibodies may later develop delayed anaemia after discharge. Families should receive written advice about poor feeding, increasing jaundice, unusual sleepiness, pallor, breathing difficulty or reduced wet nappies, with a clear pathway to urgent assessment.

Follow-up should include neurological surveillance, hearing assessment where indicated and developmental review for babies who experienced severe hyperbilirubinaemia or encephalopathy. The discharge plan must identify who will repeat blood tests and when. In Australia, arrangements may involve the tertiary hospital, local paediatric service, general practitioner and child health nurse, particularly when the family lives far from the treating centre.

Prevention And Team Communication

Prevention begins antenatally with blood-group testing, antibody screening and appropriate management of RhD-negative pregnancies. When a clinically significant antibody is detected, the obstetric and neonatal teams should plan delivery, cord blood testing, early bilirubin measurement and access to compatible blood. The plan should be visible to the maternity, laboratory and newborn teams before birth.

Clear communication is especially important when a baby has congenital or structural disease that may complicate deterioration. The prenatal diagnosis guidance reflects the wider principle that antenatal information should shape postnatal preparation. A newborn with cardiac disease, hydrops or compromised circulation may tolerate anaemia and procedural fluid shifts poorly, requiring individualised input from neonatology, cardiology and transfusion medicine.

Australian hospitals should align practice with current state or territory neonatal protocols, local bilirubin charts and transfusion policies rather than relying on an overseas threshold alone. Staff education should cover correct phototherapy use, escalation triggers, emergency blood access and the practical steps of retrieving a deteriorating newborn. Simulation exercises can reveal delays in obtaining blood, equipment or senior review before a real emergency occurs.

When bilirubin is rising rapidly or neurological signs appear, contact the neonatal consultant and transfusion laboratory immediately, start intensive phototherapy, obtain urgent blood tests and organise exchange capability without delay. Early escalation gives the baby the best chance of avoiding permanent bilirubin-related neurological injury.